Survival Evaluation in Patients Over 70 Years of Age With Advanced Stage Non-small Cell Lung Cancer

Eurasian Journal of Medical Investigation Pub Date : 2023-10-25 DOI:10.14744/ejmi.2023.29049

A. Ozturk

{"title":"Survival Evaluation in Patients Over 70 Years of Age With Advanced Stage Non-small Cell Lung Cancer","authors":"A. Ozturk","doi":"10.14744/ejmi.2023.29049","DOIUrl":null,"url":null,"abstract":"Objectives: Non-small cell lung (NSCLC) cancer is usually seen in elderly patients. The impact of over 70 age on the survival of patients with NSCLC has not been studied. This study aimed to evaluate the impact of demographic and clinical variables on survival in Stage IV the NSCLC elderly patient. Methods: This study was a retrospective cohort analysis of 244 patients with advanced stage NSCLC, between January 2015 and December 2019. The patients were classified as the <70 years and ≥70 years. The primary and secondary outcomes were the overall survival and the impact of the demographics and clinical variables on survival, respectively. Results: The numbers of patients who were <70 and ≥70 years were 136 (55.7%) and 108 (44.3%), respectively. Although the overall survival in patients aged 70 years or older was shorter than that of the younger patients, the difference was statistically insignificant (p=0.236). Weight loss, ≥2 comorbidities and TNM stage IV were significantly associated with shorter overall survival. Conclusion: Weight loss, increased comorbidities and TNM stage IV are the independent risk factors for overall survival in patients with advanced stage of NSCLC. Older age did not found any impact on survival in the study.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"72 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurasian Journal of Medical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/ejmi.2023.29049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Non-small cell lung (NSCLC) cancer is usually seen in elderly patients. The impact of over 70 age on the survival of patients with NSCLC has not been studied. This study aimed to evaluate the impact of demographic and clinical variables on survival in Stage IV the NSCLC elderly patient. Methods: This study was a retrospective cohort analysis of 244 patients with advanced stage NSCLC, between January 2015 and December 2019. The patients were classified as the <70 years and ≥70 years. The primary and secondary outcomes were the overall survival and the impact of the demographics and clinical variables on survival, respectively. Results: The numbers of patients who were <70 and ≥70 years were 136 (55.7%) and 108 (44.3%), respectively. Although the overall survival in patients aged 70 years or older was shorter than that of the younger patients, the difference was statistically insignificant (p=0.236). Weight loss, ≥2 comorbidities and TNM stage IV were significantly associated with shorter overall survival. Conclusion: Weight loss, increased comorbidities and TNM stage IV are the independent risk factors for overall survival in patients with advanced stage of NSCLC. Older age did not found any impact on survival in the study.

查看原文本刊更多论文

70 岁以上晚期非小细胞肺癌患者的生存评估

目的：非小细胞肺癌（NSCLC）通常见于老年患者。关于 70 岁以上年龄对 NSCLC 患者生存期的影响尚未进行研究。本研究旨在评估人口统计学和临床变量对 IV 期 NSCLC 老年患者生存期的影响。研究方法本研究对2015年1月至2019年12月期间的244名晚期NSCLC患者进行了回顾性队列分析。患者分为＜70岁和≥70岁。主要和次要结果分别为总生存率以及人口统计学和临床变量对生存率的影响。结果显示＜70岁和≥70岁的患者人数分别为136人（55.7%）和108人（44.3%）。虽然 70 岁或以上患者的总生存期短于年轻患者，但差异无统计学意义（P=0.236）。体重减轻、合并症≥2个和TNM分期IV与总生存期缩短显著相关。结论体重减轻、合并症增加和TNM分期IV是影响晚期NSCLC患者总生存期的独立危险因素。在这项研究中，年龄越大对生存率的影响越小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eurasian Journal of Medical Investigation

自引率

0.00%

发文量